TABLE 5.

Questions for future collaboration and study related to new asthma therapeutic targets among circulating immune mediators

What is a hypothesis that could be tested in an international collaboration and its ideal framework?

Is there a way to develop common signatures that can track patients noninvasively across clinical studies/trial cohorts?

Can harmonisation of available data in U-BIOPRED and SARP cohorts expose novel mechanisms or identify predictors of clinical response in subgroups of patients with asthma?

Is the IL-6 signature identified in the U-BIOPRED cohort similar to SARP?

Does the timing of data collection for clinical studies have an impact on clinical data collection and outcome measures such as IL-6 and other circulating mediators?

How can timing factors related to the circadian rhythm be identified and managed for accuracy?

U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes; SARP: Severe Asthma Research Program; IL-6: interleukin-6.